ARCHIVES

OMB reviewing Administration’s Reauthorization Bill; NCI Special Authority Probably Will Remain

This article is from The Cancer Letter archive.

Vol. 14 No. 16 | April 15, 1988

Download PDF Visit The Full Archive

Related Articles

Phase III Avastin Trial Fails Primary Endpoints

February 28, 2014

New Core Gant Guideline Proposals Drawn Up; Opposition Developing Among Center Directors

April 4, 1980

Avastin May Trigger Two FDA Decisions: One On Approval, Another On Withdrawal

September 3, 2010

Cediranib/Olaparib Combination Nearly Doubles PFS in Phase II

September 26, 2014

DeVita, Seffrin Present Cancer Czar PlanTo Feinstein, Without Committee Sign-Off

June 1, 2001

IOM Report Calls For FDA Authority Nutritional Supplement Health Claims

May 21, 2010